Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the
Axcella Appoints Shreeram Aradhye, M.B.B.S., M.D., as Executive Vice President, Chief Development Officer
CAMBRIDGE, Mass.–(BUSINESS WIRE)—-Axcella Health, a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism
The study was presented at ENDO 2019, Endocrine Society’s annual meeting DUARTE, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CityofHope?src=hash” target=”_blank”gt;#CityofHopelt;/agt;–The hemoglobin A1c blood test
SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the
Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox)
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s
Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
Neurotrope jumps in the Alzheimer’s solution chase, amid Biogen’s, Eisai’s dropping aducanunab trial
Neurotrope said Friday, commenting Biogen Inc.’s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer’s disease, Phase 2 clinical trial using its drug Bryostatin during the second half of 2019.
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST.